COVID-19 in ART: Perception and Experience

COVID19 Clinical Trial

— COVAPEX  

Official title:

Assessing the Perception and the Personal Experience of the COVID19 Pandemic Among Infertile Couples Undergoing Assisted Reproductive Treatment (ART)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04456010
• Other study ID #: RECHMPL20_0351
• Status: Completed
• Start date: June 1, 2020
• Est. completion date: July 30, 2020

Study information

• Verified date: December 2020
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Non-urgent medical care, such as fertility treatments, has been massively postponed during the past weeks due to the COVID19 pandemic. The lockdown and the closure of IVF centers might cause anxiety and depression among infertile couples, who are already exposed to the distressing experience of infertility and for whom the wait for a baby already appears unending. Few data are available regarding the impact of SARS-CoV-2 on pregnant women and foetus, or on fertility.

This study aims to assess the views of infertile couple regarding the potential risks of COVID during their fertility treatment and their personal experience of the COVID pandemic and their expectation for further treatment .

Recruitment information / eligibility

• Status: Completed
• Enrollment: 600
• Est. completion date: July 30, 2020
• Est. primary completion date: July 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion criteria:

• Men and women who had a fertility treatment prescribed during the past 9 months in our Fertility department

Exclusion criteria:

• Patient attending for a fertility preservation

• Patient attending for a preimplantation genetic testing (PGT-M or PGT-SR)

• Patient not fluent in French

Related Conditions & MeSH terms

• ART
• COVID19
• Fertility Issues
• Infertility

Intervention

Other:
• Questionnaire
Eligible patients will be selected from our electronical database and invited via email to participate.

Locations

Country	Name	City	State
France	Uhmontpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation	Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment, via a survey	1 day
Secondary	Risk assessment	. Risk assessment by the patient, via a survey, regarding SARS-CoV-2 during a fertility treatment or during pregnancy. Perception of the risks linked to SARS-CoV-2 during their fertility treatment or during a pregnancy	1 day
Secondary	Patients'expectations regarding the management of an abrupt closure of the fertility center	Patients'expectations regarding the management of an abrupt closure of the fertility center, via a survey	1 day